Scopolamine-induced convulsions in food given fasted mice: effects of physostigmine and MK-801

We recently reported that scopolamine pretreated mice fasted for 48 h developed clonic convulsions soon after they were allowed to eat a small amount of food for 30 s. The present experiments were performed to determine whether animals also develop convulsions when they were allowed to eat ad libitum and to find some evidence for the contribution of the cholinergic and/or glutamatergic systems in the underlying mechanism(s) of convulsions. Animals fasted for 48 h were treated with 3 mg/kg scopolamine or saline. Twenty minutes later, they were allowed to eat either ad libitum or a small portion of food for 30 s. Scopolamine pretreated animals after starting to eat ad libitum or a small amount in a restricted time developed convulsions in a few minutes, the incidence being 76 and 54%, respectively. Pretreatment of 0.17 mg/kg MK-801, the noncompetitive NMDA antagonist, decreased the incidence of scopolamine-induced convulsions (22%) without affecting latency to the onset of seizures. Pretreatment of 0.1 mg/kg physostigmine, the cholinesterase inhibitor, changed neither the incidence (90%) nor latency to the onset of scopolamine-induced convulsions.

[1]  D. Johnston,et al.  Muscarinic depression of synaptic transmission at the hippocampal mossy fiber synapse. , 1990, Journal of neurophysiology.

[2]  W. Walter,et al.  Electrically Induced Convulsions , 1940 .

[3]  T. Kameyama,et al.  Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. , 1991, European journal of pharmacology.

[4]  R. Wurtman,et al.  N-methyl-D-aspartate increases acetylcholine release from rat striatum and cortex: its effect is augmented by choline. , 1992, The Journal of pharmacology and experimental therapeutics.

[5]  M. Piercey,et al.  Reversal of scopolamine-induced amnesia and alterations in energy metabolism by the nootropic piracetam: implications regarding identification of brain structures involved in consolidation of memory traces , 1987, Brain Research.

[6]  D. Beleslin,et al.  Nicotine-induced convulsions in cats and central nicotinic receptors , 1986, Pharmacology Biochemistry and Behavior.

[7]  D. Purpura,et al.  Experimental Models of Epilepsy--a Manual for the Laboratory Worker , 1972 .

[8]  Mice housed in a cage with a maze learn the maze without explicit training , 1992, Pharmacology Biochemistry and Behavior.

[9]  D. Braitman,et al.  Dizocilpine (MK-801) arrests status epilepticus and prevents brain damage induced by soman , 1992, Neuropharmacology.

[10]  A. Płażnik,et al.  Effects of antagonists at the NMDA receptor complex in two models of anxiety , 1994, European Neuropsychopharmacology.

[11]  W. Löscher,et al.  Antagonism of N-methyl-D,L-aspartic acid-induced convulsions by antiepileptic drugs and other agents. , 1985, European journal of pharmacology.

[12]  Z. Bortolotto,et al.  Seizures produced by pilocarpine in mice: A behavioral, electroencephalographic and morphological analysis , 1984, Brain Research.

[13]  E. J. Drenick,et al.  Resistance to insulin convulsions in fasted mice. , 1973, Endocrinology.

[14]  T. Bártfai,et al.  Muscarinic autoreceptor regulates acetylcholine release in rat hippocampus: in vitro evidence. , 1980, Acta physiologica Scandinavica.

[15]  Robert S. Fisher,et al.  Animal models of the epilepsies , 1989, Brain Research Reviews.

[16]  D. Lodge,et al.  Effect of ketamine on amino acid-evoked release of acetylcholine from rat cerebral cortex in vitro , 1985, Neuroscience Letters.

[17]  B. Scatton,et al.  N-methyl-D-aspartate-type receptors mediate striatal 3H-acetylcholine release evoked by excitatory amino acids , 1982, Nature.

[18]  V. Doležal,et al.  Muscarinic receptor blockade increases basal acetylcholine release from striatal slices. , 1990, The Journal of pharmacology and experimental therapeutics.

[19]  M. T. Shipley,et al.  Pilocarpine-Induced Convulsions in Rats: Evidence for Muscarinic Receptor-Mediated Activation of Locus Coeruleus and Norepinephrine Release in Cholinolytic Seizure Development , 1993, Experimental Neurology.

[20]  P. Ornstein,et al.  N-Methyl-d-aspartic acid-induced lethality in mice: selective antagonism by phencylidine-like drugs , 1988, Brain Research.

[21]  D. R. Anderson,et al.  Efficacy of injectable anticholinergic drugs against soman-induced convulsive/subconvulsive activity. , 1994, Drug and chemical toxicology.

[22]  F. Bymaster,et al.  Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[23]  S. Miyazaki,et al.  The effects of anxiolytics and anxiogenics on evaluation of learning and memory in an elevated plus-maze test in mice. , 1995, Methods and findings in experimental and clinical pharmacology.

[24]  R. Corbett,et al.  Yohimbine-induced seizures involve nmda and gabaergic transmission , 1992, Neuropharmacology.

[25]  S. Sparenborg,et al.  Pharmacological dissociation of the motor and electrical aspects of convulsive status epilepticus induced by the cholinesterase inhibitor soman , 1993, Epilepsy Research.

[26]  S. Woods,et al.  Penetration of peripheral glucose and insulin into cerebrospinal fluid in rats. , 1988, The American journal of physiology.

[27]  John W. Miller,et al.  Characterization of cholinergic regulation of seizures by the midline thalamus , 1992, Neuropharmacology.